LATEST NEWS
September 26, 2024 | Company Announcements
Bavarian Nordic Signs Agreement with UNICEF for 1 Million Mpox Vaccines September 26, 2024 | Company Announcements
Bavarian Nordic Upgrades its Financial Guidance for 2024September 24, 2024 | Company Announcements
Bavarian Nordic Awarded USD 63 Million from the U.S. Government for Production and Supply of Additional Smallpox/Mpox Vaccines September 19, 2024 | Press Releases
Bavarian Nordic Receives EMA Approval of Mpox Vaccine for AdolescentsSeptember 18, 2024 | Company Announcements
Gavi Signs Agreement with Bavarian Nordic to Rapidly Secure 500,000 Doses of Mpox Vaccines for AfricaSeptember 13, 2024 | Company Announcements
Bavarian Nordic Receives WHO Prequalification for Mpox VaccineSeptember 12, 2024 | Press Releases
Bavarian Nordic Provides Update on the Mpox Vaccine Supply SituationSeptember 05, 2024 | Press Releases
First Doses of Bavarian Nordic’s Mpox Vaccine Now Arriving in the Democratic Republic of CongoSeptember 05, 2024 | Company Announcements
Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant ExerciseAugust 27, 2024 | Press Releases
Bavarian Nordic Receives Approval of Smallpox and Mpox Vaccine in Singapore